このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Addex Therapeutics マネジメント

マネジメント基準チェック /24

Addex Therapeutics'の CEO はTim Dyerで、 Jan2002年に任命され、の在任期間は 22.42年です。は、会社の株式の11.95%を直接所有しており、その価値はCHF 950.34K 。経営陣と取締役会の平均在任期間はそれぞれ7.3年と9年です。

主要情報

Tim Dyer

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	22.5yrs
CEOの所有権	15.6%
経営陣の平均在職期間	7.4yrs
取締役会の平均在任期間	9.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Addex Therapeutics の収益と比較して、Tim Dyer の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-CHF 11m
Dec 31 2023	n/a	n/a	-CHF 11m
Sep 30 2023	n/a	n/a	-CHF 9m
Jun 30 2023	n/a	n/a	-CHF 11m
Mar 31 2023	n/a	n/a	-CHF 15m
Dec 31 2022	n/a	n/a	-CHF 21m
Sep 30 2022	n/a	n/a	-CHF 22m
Jun 30 2022	n/a	n/a	-CHF 21m
Mar 31 2022	n/a	n/a	-CHF 19m
Dec 31 2021	n/a	n/a	-CHF 15m
Sep 30 2021	n/a	n/a	-CHF 13m
Jun 30 2021	n/a	n/a	-CHF 13m
Mar 31 2021	n/a	n/a	-CHF 11m
Dec 31 2020	CHF 917k	CHF 454k	-CHF 13m
Sep 30 2020	n/a	n/a	-CHF 14m
Jun 30 2020	n/a	n/a	-CHF 15m
Mar 31 2020	n/a	n/a	-CHF 16m
Dec 31 2019	CHF 709k	CHF 429k	-CHF 15m
Sep 30 2019	n/a	n/a	-CHF 13m
Jun 30 2019	n/a	n/a	-CHF 12m
Mar 31 2019	n/a	n/a	-CHF 6m
Dec 31 2018	CHF 2m	n/a	-CHF 2m

報酬と市場: Timの総報酬がUK市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Timの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Tim Dyer (56 yo)

22.5yrs

在職期間

Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Timothy Dyer	Co-Founder	22.5yrs	データなし	15.59% CHF 965.7k
Roger Mills	Chief Medical Officer & Director	7.7yrs	データなし	データなし
Lénaic Teyssédou	Head of Finance	7.1yrs	データなし	データなし
Mikhail Kalinichev	Head of Translational Science	2.9yrs	データなし	データなし

7.4yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: 0QNVの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Timothy Dyer	Co-Founder	9.5yrs	データなし	15.59% CHF 965.7k
Roger Mills	Chief Medical Officer & Director	7.5yrs	データなし	データなし
Isaac Manke	Independent Director	6.1yrs	CHF 41.29k	データなし
Raymond Hill	Non-Executive Director	9.1yrs	CHF 89.65k	1.39% CHF 86.0k
Vincent Lawton	Independent Chairman of the Board	15.3yrs	CHF 155.75k	2.55% CHF 158.0k

9.1yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: 0QNVの取締役会は経験豊富であると考えられます ( 9年の平均在任期間)。

Addex Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Recent updates

Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium

Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024

Full year 2023 earnings released: CHF0.14 loss per share (vs CHF0.46 loss in FY 2022)

Insufficient new directors

Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders

New major risk - Shareholder dilution

Insufficient new directors

Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million.

Insufficient new directors

Addex Therapeutics Ltd to Report First Half, 2024 Results on Aug 12, 2024

Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance

Addex Therapeutics Announces Data Published in Brain

Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

No longer forecast to breakeven

Addex Regains Nasdaq Listing Compliance

No longer forecast to breakeven

No longer forecast to breakeven

Addex Therapeutics Ltd to Report Fiscal Year 2022 Results on Mar 13, 2023

No longer forecast to breakeven

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Addex Therapeutics Ltd announced that it has received funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive funding from Armistice Capital LLC

No longer forecast to breakeven

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate

Addex Therapeutics Ltd Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

First quarter 2022 earnings released: CHF0.15 loss per share (vs CHF0.079 loss in 1Q 2021)

Forecast to breakeven in 2024

Addex Therapeutics Ltd Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Addex Therapeutics Ltd Expands Pipeline with Selective M4 Positive Allosteric Modulator Program

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Addex Therapeutics Ltd, Annual General Meeting, May 09, 2022

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Addex Therapeutics Ltd announced that it has received CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics Ltd announced that it expects to receive CHF 5.427937 million in funding from Armistice Capital LLC

Addex Therapeutics Ltd Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

Addex Therapeutics Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia

First quarter 2021 earnings released: CHF0.08 loss per share (vs CHF0.16 loss in 1Q 2020)

Revenue beats expectations

Full year 2020 earnings released: CHF0.48 loss per share (vs CHF0.56 loss in FY 2019)

Addex Therapeutics Ltd to Report Q1, 2021 Results on May 03, 2021

Enamine Ltd. Extends Collaboration with Addex Therapeutics Ltd

Addex Therapeutics Announces New Treatment Option for Severe Alcohol Use Disorder

Addex Therapeutics Ltd to Report Fiscal Year 2020 Results on Mar 08, 2021

Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

Addex Therapeutics Ltd to Report Q3, 2020 Results on Nov 03, 2020

First half earnings released

Addex Therapeutics Ltd to Report First Half, 2020 Results on Aug 12, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24